MedTrace Logo

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

NCT07161843 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-02-18

No results posted yet for this study

Summary

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Conditions

  • Acute Renal Failure (ARF)
  • Acute Tubular Necrosis

Interventions

DRUG

QRX-3

Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Sponsors & Collaborators

  • Ebima Clifford Okundaye

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2026-12-30
Completion
2027-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07161843 on ClinicalTrials.gov